Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial

References

• UNAIDS Global Report. http://www.unaids.org/en/resources/documents/2014/HIV_estimates_with_uncertainty_bounds_1990-2013. Accessed November 26, 2014..
   Google Scholar
• d'Arminio Monforte A, González L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL, et al. Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS. 2010;24:1091–1094.
   PubMed Web of Science ®Google Scholar
• The American College of Obstetricians and Gynecologists. Gynecologic care for women with human immunodeficiency virus. Practice Bulletin Number 117. Obstet Gynecol. December 2010;116:1492–1509.
   PubMedGoogle Scholar
• Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41:256–262.
   PubMed Web of Science ®Google Scholar
• Harris RZ, Benet LZ, Schwartz JB. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther. 1996;59:429–435.
   PubMed Web of Science ®Google Scholar
• Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr. 2000;24:316–324.
   PubMed Web of Science ®Google Scholar
• Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075–1083.
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS. Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007;8:371–380.
   PubMed Web of Science ®Google Scholar
• Da Silva B, Cohen D, Gibbs S, Fredrick L, Bernstein B. Impact of gender on response to lopinavir/ritonavir (LPV/r) tablets dosed QD or BID administered with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in antiretroviral-naıve (ARV) subjects: Results from study M05-730. Presented at: 17th International AIDS Conference, August 3–8, 2008; Mexico City, Mexico. [Poster TUPE0069]..
   Google Scholar
• Eluwa GI, Badru T, Akpoigbe KJ. Adverse drug reaction to antiretroviral therapy [ARV]: incidence, type and risk factors in Nigeria. BMC Clin Pharmacol. 2012;12:1472–6904.
   Google Scholar
• Dong BJ, Zheng Y, Hughes MD, Frymoyer A, Verotta D, Lizak P, et al. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012;26:833–841.
   PubMed Web of Science ®Google Scholar
• Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevarapine use in HIV-infected subjects. J Inf Dis. 2005;191:825–829.
   PubMed Web of Science ®Google Scholar
• Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, et al. Risk factors for symptoms hyperlactemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. Aids Res Hum Retroviruses. 2012;28:759–765.
   PubMed Web of Science ®Google Scholar
• Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first- line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr. 2011;56:59–63.
   PubMed Web of Science ®Google Scholar
• Squires KE. Gender differences in the diagnosis and treatment of HIV. Gend Med. 2007;4:294–307.
   PubMed Web of Science ®Google Scholar
• Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. A randomised clinical trial of the efficacy and safety of once-daily antiretroviral therapy for initial treatment of HIV-1 infection in diverse multinational settings: the ACTG PEARLS Study. PLoS Med. 2012;9:e1001290.
   PubMed Web of Science ®Google Scholar
• Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events. DAIDS RSC; 2004. http://rsc.tech-res.com/safetyandpharmacovigilance/.
   Google Scholar
• Grinsztejn B, Smeaton L, Barnett R, Klingman K, Hakim J, Flanigan T, et al. Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4 (+) T-cell count. Antivir Ther. 2011;16:1057–1062.
   PubMed Web of Science ®Google Scholar
• Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, Shapiro DE, et al. Assessment of safety and toxicity following maternal antiretroviral exposure in infants born to HIV-infected women enrolled in antiretroviral treatment protocols in diverse areas of the world. Eighteen month results of AIDS Clinical Trials Group [ACTG] Study 5190/Pediatric AIDS Clinical Trials Group (PACTG) 1054. Pediatrics. 2012;129:e1525–e1532.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE Study. J Acquir Immune Defic Syndr. 2010;53:323–332.
   PubMed Web of Science ®Google Scholar
• Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr. 2003;32:452–461.
   PubMed Web of Science ®Google Scholar
• Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS. 2005;19:357–370.
   PubMed Web of Science ®Google Scholar
• Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS. 2005;19:577–583.
   PubMed Web of Science ®Google Scholar
• Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother. 2007;60:724–732.
   PubMed Web of Science ®Google Scholar
• Sekar V, Ryan R, Schaible D, Mazikewich A, Mrus J. Pharmacokinetic profile of darunavir (DRV) co-administered with low dose ritonavir in treatment experienced women and men: 4 week analysis in a substudy of the GRACE trial. Presented at: 9th International Workshop on Clinical Pharmacology of HIV Therapy (IWCPHIV); April 7–9, 2008; New Orleans, LA..
   Google Scholar
• Burger DM, Siebers MC, Hugen PW, Aamoutse RE, Hekster YA, Koopmans PP. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr. 2002;29:101–102.
   PubMed Web of Science ®Google Scholar
• Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004;189:1176–1184.
   PubMed Web of Science ®Google Scholar
• Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis. 2014;58:555–563.
   PubMed Web of Science ®Google Scholar
• Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, et al. Psychol social Predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: Data from the ACTG A5175/PEARLS trial. Plos One. 2014;9:e104178.
   PubMed Web of Science ®Google Scholar
• Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66:363–370.
   PubMed Web of Science ®Google Scholar
• Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, Yepthomi T, et al. Gender-based differences in treatment and outcome among HIV patients in South India. J Womens Health. 2008;17:1471–1475.
   PubMed Web of Science ®Google Scholar
• Hawkins C, Chalamilla G, Okuma J, Spiegelman D, Hertzmark E, Aris E, et al. Gender differences in antiretroviral treatment outcomes among HIV-infected adults in Dar es Salaam, Tanzania. AIDS. 2011;25:1189–1197.
   PubMed Web of Science ®Google Scholar
• Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian K, Siika AM, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681–688.
   PubMed Web of Science ®Google Scholar
• Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43:78–84.
   PubMed Web of Science ®Google Scholar
• Johannessen A. Are men the losers of the antiretroviral treatment scale-up? AIDS. 2011;25:1225–1226.
   PubMed Web of Science ®Google Scholar
• Farley J, Miller E, Zamani A, Tepper V, Morris C, Oyegunle M, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care. 2010;9:218–226.
   Google Scholar
• Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, et al. Sex-based outcomes of Darunavir-Ritonavir therapy: The GRACE (gender, race, and clinical experience) study. Ann Intern Med. 2010;153:349–357.
   PubMed Web of Science ®Google Scholar
• Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, et al. Safety, tolerability, and efficacy of raltegravir (RAL) in a diverse cohort of HIV-infected patients (pts): 48 week results from the REALMRK study. AIDS Res Hum Retroviruses. 2013;29:859–870.
   PubMed Web of Science ®Google Scholar